Integrated Continuous Biomanufacturing VII
The Integrated and Continuous Biomanufacturing (ICB) Conference is the exclusive worldwide meeting for all interested parties from industry, academia and health authorities to exchange latest advancements in this field that is revolutionizing biopharmaceutical production. The seventh conference in this series shows how quickly these developments are progressing. In previous years, there was debate about whether integrated biomanufacturing could be implemented and whether it made economic sense. Today, the discussion is about how we can achieve an autonomous bioprocess with integrated continuous biomanufacturing, commercial-scale, GMP manufacturing campaigns and the application of continuous bioproduction concepts for production of new modalities. Potential impacts on cost of goods, environmental footprint, process development approaches, and regulatory strategy will be key areas for further exploration together as a community.
ICB VII will provide a platform to exchange ideas and latest development of exciting new integrated and continuous processes including: case studies of successful implementation, applications of ICB to bionanoparticles, potential to modulate product quality leveraging ICB, advances in cell culture and high-resolution purification unit operations, and opportunities to leverage data science to better realize ICB processes. Matching the enthusiasm on the topic in the bioprocessing community, emphasis will also be placed on process modeling and new concepts of process control leveraging machine learning, artificial intelligence and soft sensors as an important element of the conference. As in previous years, strong interaction of health authorities will also help the community to understand how these new technologies can be placed within the regulatory framework.
Most of all, we look forward to the many opportunities for direct interaction between ICB VII participants.
On behalf of the ICB Conference Steering Committee, we are pleased to announce that ICB VII will be held in Dubrovnik, Croatia in October of 2025. This will return the biannual conference series to ‘odd’ calendar years. We cordially invite you to get involved in this interesting event, as a presenter, participant, sponsor, or member of the organizing committee.
Sincerely,
Irina Ramos, Kevin Brower, Mark Brower, Alois Jungbauer
Conference Chairs
Conference Organization
Conference Chairs
Kevin Brower, Sanofi (USA)
Mark Brower, Merck (USA)
Alois Jungbauer, BOKU (Austria)
Irina Ramos, Johnson & Johnson (USA)
Organizing Committee
Veronique Chotteau, KTH Royal Institute of Technology (Sweden)
David Garcia, Novartis Pharma (Switzerland)
Eva Gefroh, Just-Evotec Biologics, Inc (USA)
Caryn Heldt, Michigan Technicalogical University (USA)
Karol Lacki, Repligen (Sweden)
Ken Lee, AstraZeneca (USA)
Dong-Qiang Lin, Zhejiang University (China)
Maria M. Papathanasiou, Imperial College London (UK)
Maarten Pennings, Biosana Pharma (Netherlands)
Nuno Pinto, Merck & Co., Inc. (USA)
Weichang Zhou, WuXi Biologics (China)
Steering Committee
Ana M. Azevedo, Instituto Superior Técnico (Portugal)
Jonathan Coffman, AstraZeneca (USA)
Charles L. Cooney, Massachusetts Institute of Technology (USA)
Rohini R. Deshpande, Amgen, Inc (USA)
Suzanne S. Farid, University College London (UK)
Chetan T. Goudar, Amgen, Inc (USA)
Alois Jungbauer, BOKU (Austria)
Konstantin B. Konstantinov, Ring Therapeutics (USA)
Aaron Noyes, Apogee Therapeutics (USA)
Gene Schaefer, NIIMBL (USA)
Jason Walther, Sanofi (USA)
Veena Warikoo, AstraZeneca (USA)